Physician profile
Mark L Perman
NPI 1912982802
$1,113.79
in general payments reported to CMS, 2019-2025
10 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $141 · 2021: $213 · 2022: $351 · 2023: $108 · 2024: $51.50 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $278.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $374.28 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $361.07 | 2019-2024 | Tagrisso |
| Advanced Accelerator Applications | $105.81 | 2020 | |
| Telix Pharmaceuticals | $93.71 | 2025 | Illuccix |
| Myriad Genetic Laboratories, INC. | $70.70 | 2021-2022 | |
| Fortovia Therapeutics, INC. | $27.21 | 2019 | |
| Blue Earth Diagnostics | $25.65 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.07 | 2025 | |
| Palette Life Sciences, INC. | $17.64 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Perman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.